Quantum Biopharma annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Quantum Biopharma R&D Spending Growth & History (QNTM)
Quantum Biopharma's r&d spending was $2.8M for fiscal 2025.
View full Quantum Biopharma company overviewQuantum Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.8M | −$3.3M | −54.58% |
| 2024 | 2024-12-31 | $6.1M | $2.2M | +57.63% |
| 2023 | 2023-12-31 | $3.9M | −$3.1M | −44.16% |
| 2022 | 2022-12-31 | $6.9M | $582,740 | +9.21% |
| 2021 | 2021-12-31 | $6.3M | −$1.5M | −19.21% |
| 2020 | 2020-12-31 | $7.8M | $7.8M | — |
| 2019 | 2019-12-31 | $0 | — | — |
Quantum Biopharma quarterly r&d spending
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $387,428 | −$161,769 | −29.46% |
| Q1 2026 | 2026-03-31 | $626,092 | −$1.0M | −62.02% |
| Q4 2025 | 2025-12-31 | $70,404 | −$4.2M | −98.36% |
| Q3 2025 | 2025-09-30 | $495,223 | −$249,579 | −33.51% |
| Q2 2025 | 2025-06-30 | $549,197 | −$348,789 | −38.84% |
| Q1 2025 | 2025-03-31 | $1.6M | $1.5M | +928.55% |
| Q4 2024 | 2024-12-31 | $4.3M | — | — |
| Q3 2024 | 2024-09-30 | $744,802 | $711,817 | +2158.00% |
| Q2 2024 | 2024-06-30 | $897,986 | −$712,542 | −44.24% |
| Q1 2024 | 2024-03-31 | $160,260 | — | — |
| Q3 2023 | 2023-09-30 | $32,985 | — | — |
| Q2 2023 | 2023-06-30 | $1.6M | — | — |
Quantum Biopharma r&d spending trends
Over the last five fiscal years, Quantum Biopharma's r&d spending decreased from $7.8M to $2.8M, a change of −$5.1M. The latest reported quarter, Q2 2026, shows $387,428.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quantum Biopharma source filings ↗